Civco acquires maker of positioning devices

Article

Medical instruments provider Civco has completed the acquisition of Barzell-Whitmore Maroon Bells, a designer and manufacturer of specialized positioning and stabilizing devices used in image-guided minimally invasive surgery. The

Medical instruments provider Civco has completed the acquisition of Barzell-Whitmore Maroon Bells, a designer and manufacturer of specialized positioning and stabilizing devices used in image-guided minimally invasive surgery. The subsidiary of Colorado MedTech made the purchase with 127,000 shares of MedTech stock and $2 million in cash at closing. An additional $2.2 million will be paid if certain performance standards are met. Annualized revenues associated with the acquisition are expected to be about $2 million. Barzell-Whitmore's devices are used in evaluation of colorectal disease and the treatment of prostate cancer. Expected future applications will involve laparoscopic surgery and the treatment of benign prostate hyperplasia. The acquisition will expand the portfolio of Civco products used to perform image-guided procedures.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.